Aptose Biosciences 10-K: No Revenue, Net Loss $(25.468) M, EPS $(10.41)
I'm LongbridgeAI, I can summarize articles.Aptose Biosciences reported no revenue for the year ended December 31, 2025, with a net loss of $25.468 million, translating to a net loss per share of $10.41. The losses stemmed from research and development and administrative expenses. The company advanced its lead program, tuspetinib, into a frontline trial, demonstrating a favorable safety profile. Additionally, it entered a partnership with the National Cancer Institute and secured a supply agreement with Hanmi. Shareholders approved an acquisition arrangement at C$2.41 per share, pending delisting from the TSX.
Aptose Biosciences reported no revenue for the year ended December 31, 2025 and posted a net loss of $25.468 million, equivalent to net loss per common share of $10.41. The company recorded operating losses driven by research and development and general and administrative expenses. The filing outlines clinical and operational progress on its lead program while detailing corporate and manufacturing actions supporting ongoing trials.
Financial Highlights
- Revenues: $— (no revenue reported for the years ended Dec 31, 2025 and 2024)
- Operating Income: $— (not presented; R&D $11.341M and G&A $13.382M resulted in an operating loss)
- Net Income: $(25.468) million (net loss and comprehensive loss for the year ended Dec 31, 2025)
- Net loss per common share, basic and diluted: $(10.41) (for the year ended Dec 31, 2025)
Business Highlights
- Clinical Progress: Advanced tuspetinib through Phase 1/2 into a frontline combination trial (TUS+VEN+AZA, “TUSCANY”), reporting multiple complete remissions and high rates of MRD‑negativity across diverse AML mutations.
- Safety & Differentiation: Tuspetinib demonstrated a favorable safety profile with no dose‑limiting toxicities, no QTc signal, and no differentiation syndrome observed, supporting dose escalation to 160 mg and enabling outpatient oral dosing.
- Partnerships & Trials: Entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to support MyeloMATCH trials and completed an international APTIVATE expansion to broaden clinical sites and investigator engagement.
- Manufacturing & Supply: Secured existing drug product inventory and a supply agreement with Hanmi; additional API and drug product batches were produced to support ongoing clinical trials.
- Corporate Actions & Market Access: Shareholders approved an arrangement with Hanmi to acquire the company at C$2.41 per share, with subsequent delisting from the TSX pending closing of the arrangement.
Original SEC Filing: Aptose Biosciences Inc. [ APTOF ] - 10-K - Mar. 31, 2026